BeOne Medicines AG declines as stock hits 20-day low
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 Dec 25
Source: SeekingAlpha
BeOne Medicines AG's stock fell by 3.24% today, hitting a 20-day low amid a generally positive market environment where the Nasdaq-100 rose by 0.14% and the S&P 500 gained 0.15%.
This decline occurs despite the broader market strength, suggesting sector rotation as investors may be reallocating their portfolios away from biotech stocks. The overall market's upward movement contrasts with BeOne Medicines AG's performance, indicating a shift in investor sentiment.
The implications of this movement could reflect a cautious approach towards biotech investments, as investors might be focusing on sectors that are currently performing better in the market.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 403.76 USD with a low forecast of 385.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 350.000
Low
385.00
Averages
403.76
High
424.00
Current: 350.000
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
